| Similar Articles |
|---|
 |
Fast Company
November 2015
Max Chafkin |
How Failed JC Penney CEO Ron Johnson Is Redeeming Himself With Enjoy The company sells consumer electronics via the web and has its couriers, or "Experts," in Johnson's parlance, act as modern-day Maytag Men, hand-delivering the items in as little as four hours.   |
IEEE Spectrum
May 2006
Lauren Aaronson |
Parallel Processor How IBM engineer Sandra Johnson contributes to her field, her business, and the community. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues. |
Outside
February 2002
Bill Donahue |
End of the Run In Sarajevo, Bill Johnson won America's first Olympic gold medal in the downhill with an astonishing kamikaze performance. Now, in the wake of a comeback attempt that almost killed him, skiing's crash-course survivor struggles with the consequences of a life lived too fast... |
The Motley Fool
January 18, 2012 |
What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
Inc.
April 2004
Alison Stein Wellner |
Case Study Colin Johnson had a bold plan to transform his consulting firm. But when things went awry, sticking to his guns meant risking everything. |
| Knowledge@Wharton |
The Bob Johnson Factor: How the BET Founder Is Building an Empire Entrepreneurs with good ideas and the right timing can find capital to finance their business if they build strong support networks, according to Robert L. Johnson, founder and chief executive of Black Entertainment Television. |
The Motley Fool
July 12, 2011
Todd Wenning |
What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors. |
Reason
July 2002
John J. Pitney Jr. |
New Criticism A history of the 1990s, Haynes Johnson's The Best of Times: America in the Clinton Years, misses the good old days -- and the truth. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales? |
Financial Planning
June 1, 2010
Jim Grote |
Under One Roof Timothy E. Johnson has grown his business by listening to his clients' needs-and creating an in-house solution for each of them. |
The Motley Fool
July 31, 2007
Nathan Parmelee |
Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business. |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
The Motley Fool
August 14, 2007
Brian Orelli |
A No-Win Situation Johnson & Johnson is suing the beloved American Red Cross for trademark infringement. Johnson & Johnson just needs to walk a fine line between having its brand eroded by the Red Cross and having its brand eroded by a public relations nightmare. |
The Motley Fool
December 1, 2010
Brian Orelli |
We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell. |
Outside
September 2005
Brian Alexander |
Jack Out of the Box America's multiplatinum surf troubadour Jack Johnson rides his dreams like a North Shore break. His secret? If you love what you do, life and work can both be a rip. |
Sports Central
October 8, 2011
David Exum |
Don't Count Out Jimmie Johnson I don't think I'll ever understand why some race fans can't embrace five-time and defending NASCAR Sprint Cup champion Jimmie Johnson. |
Outside
June 2010
Michael Roberts |
Iron Jack In which Jack Johnson, the world's favorite sunny-day-at-the-beach singer, morphs into a hardened wild man with help from a surprising piece of inspiration. (Don't worry, his new music still goes perfectly with coconuts.) |
The Motley Fool
February 28, 2011
Brian Orelli |
Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
March 24, 2011
Anand Chokkavelu |
Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund." |
The Motley Fool
August 24, 2010
Brian Orelli |
One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well. |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
November 21, 2008
Brian Orelli |
Manufacturing Pain Johnson & Johnson has plenty of it. |
The Motley Fool
July 9, 2010
Brian Orelli |
Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products. |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
August 19, 2010
Brian Orelli |
Buffett Is Buying J&J. Should You? It depends on your time horizon. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
HBS Working Knowledge
May 15, 2006
Diane Coutu |
LBJ's Deliberate March for Power When a leader gets enough power -- when he's president of the United States or CEO of a major corporation -- then we can see what he wanted to accomplish all along. Here, a Harvard expert discusses Lyndon B. Johnson's strategy for getting close to powerful people. |
The Motley Fool
November 17, 2006
Brian Lawler |
Johnson & Johnson's Good Deal If Conor's stent design can alleviate some of the perceived safety worries about stents, then sales from the Cordis division should spring back up, again making it drive revenue growth for Johnson & Johnson, as it did before this year. Investors, take note. |
The Motley Fool
September 14, 2007
Brian Orelli |
J&J's Expensive RNA Purchase Johnson & Johnson sets up a collaboration with Isis Pharmaceuticals to develop compounds to treat diabetes. Investors take note. |
The Motley Fool
January 23, 2008
Brian Orelli |
A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar. |
The Motley Fool
May 28, 2010
Brian Orelli |
How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem? |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
The Motley Fool
June 25, 2010
Brian Orelli |
The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error. |
The Motley Fool
September 30, 2009
Brian Orelli |
Boston Scientific Pays Up And Johnson & Johnson reaps the rewards. |
The Motley Fool
September 14, 2009
Brian Orelli |
The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri. |
Entrepreneur
June 2004
Amanda C. Kooser |
How Tech Got Its Groove Back After the dotcom bust, the tech industry is picking itself up and dusting itself off for another dance--with the help of some innovative entrepreneurs. |
The Motley Fool
December 17, 2009
Brian Orelli |
This Acquisition Hears, Smells, and Tastes Soooo Good Johnson & Johnson picks up an ear, nose, and throat medical device maker. |
The Motley Fool
August 3, 2005
Steven Mallas |
JNJ: One to Monitor Johnson & Johnson might not exactly be a bargain, but it should always be on your stock watch list. |
The Motley Fool
February 8, 2006
Nathan Slaughter |
Best Blue Chip: Johnson & Johnson In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: it is easy to see why Johnson & Johnson, deserves to carry home the gold. |
The Motley Fool
January 26, 2011
Brian Orelli |
J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot. |
The Motley Fool
June 15, 2011
Brian Orelli |
Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market. |
Salon.com
April 24, 2001
Jake Tapper |
Virtually NORML Gov. Gary Johnson comes to Washington hoping to find converts to his anti-drug war crusade. He leaves one frustrated man... |
Fast Company
June 2002
Alison Overholt |
Mr. Patent Marvin Johnson can't seem to stop innovating. The plainspoken scientist from Phillips Petroleum has 212 patents to his name. Here are the surprising secrets of his creative success... |
The Motley Fool
April 29, 2011
David Williamson |
Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes. |
The Motley Fool
July 12, 2010
Brian Orelli |
Johnson & Johnson MENDs a Hole Another neurovascular device maker, Micrus Endovascular, gets snatched up. |
